Sinopharm Group Co Ltd
HKEX:1099
Intrinsic Value
Sinopharm Group Co., Ltd. is a distributor of pharmaceutical and healthcare products and a value added supply chain service provider in the People's Republic of China. [ Read More ]
The intrinsic value of one
Sinopharm Group Co Ltd
stock under the Base Case scenario is
92.2
HKD.
Compared to the current market price of 21.2 HKD,
Sinopharm Group Co Ltd
is
Undervalued by 77%.
Sinopharm Group Co Ltd could be a value trap.A value trap occurs when a stock looks inexpensive based on fundamental analysis but fails to reach its intrinsic valuation over time, often due to underlying issues not reflected in quantitative data.
Scrutinize beyond numbers; assess long-term potential.
Sinopharm Group Co Ltd's market capitalization is 66.2B HKD.
Sinopharm Group Co Ltd stock price is 21.2 HKD.
Sinopharm Group Co Ltd stock price (21.2 HKD) is 77% less than its Intrinsic Value (92.2 HKD).
Sinopharm Group Co Ltd stock price (21.2 HKD) is 74% less than its DCF Value (80.32 HKD). Open DCF Valuation
Sinopharm Group Co Ltd stock price (21.2 HKD) is 80% less than its Relative Value (104.07 HKD). Open Relative Valuation
Sinopharm Group Co Ltd has upside potential of 31% compared to the average analyst price target.
Open Wall St Estimates
Sinopharm Group Co Ltd's ROE (Return on Equity) has decreased in the last 3 years from 14% to 13%.
Sinopharm Group Co Ltd's ROIC (Return on Invested Capital) for the past 12 months is positive and is equal to 8%.
Sinopharm Group Co Ltd has positive Gross Profit for the last twelve months.
Sinopharm Group Co Ltd has positive three-year average ROIC (Return on Invested Capital): 9%. The company is efficient at using invested capital to generate operating income.
Sinopharm Group Co Ltd's ROIC (Return on Invested Capital) has decreased in the last 3 years from 11% to 8%.
Sinopharm Group Co Ltd's ROE (Return on Equity) for the past 12 months is positive and is equal to 13%.
Sinopharm Group Co Ltd's Revenue has grown by 11% over the past 12 months.
Sinopharm Group Co Ltd has positive Free Cash Flow for the last twelve months.
Sinopharm Group Co Ltd's long-term assets (418B CNY) exceed its long-term liabilties (348B CNY).
Sinopharm Group Co Ltd has positive three-year average ROE (Return on Equity): 13%. The company is efficient at transforming stockholders' equity into net income.
Sinopharm Group Co Ltd's Revenue is forecast to grow at a rate of 10% per year over the next 3 years.
Sinopharm Group Co Ltd's short-term assets (372B CNY) exceed its short-term liabilties (281B CNY).
Sinopharm Group Co Ltd has positive Operating Income for the last twelve months.
Sinopharm Group Co Ltd's Revenue has been growing by 11% per year for the last 3 years.
Sinopharm Group Co Ltd has positive Net Income for the last twelve months.
Sinopharm Group Co Ltd's Altman Z-Score is equal to 2.11.
Sinopharm Group Co Ltd has negative Net Debt. This means that the company has more cash and short-term investments (34B CNY) than debt (19B CNY).
Sinopharm Group Co Ltd's D/E (Debt to Equity) is very low and is equal to 0.27.
Sinopharm Group Co Ltd generates enough operating income (23B CNY) to cover interest payments on its debt (4B CNY).
Valuation Backtest
Sinopharm Group Co Ltd
Run backtest to discover the historical profit from buying and selling
Sinopharm Group Co Ltd
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Sinopharm Group Co Ltd
Balance Sheet Decomposition
Sinopharm Group Co Ltd
| Current Assets | 372.2B |
| Cash & Short-Term Investments | 34.4B |
| Receivables | 241.5B |
| Other Current Assets | 96.3B |
| Non-Current Assets | 45.5B |
| Long-Term Investments | 10.6B |
| PP&E | 19.7B |
| Intangibles | 10.1B |
| Other Non-Current Assets | 5.1B |
| Current Liabilities | 281.3B |
| Accounts Payable | 156.6B |
| Accrued Liabilities | 35.2B |
| Other Current Liabilities | 89.5B |
| Non-Current Liabilities | 66.8B |
| Long-Term Debt | 18.5B |
| Other Non-Current Liabilities | 48.2B |
Earnings Waterfall
Sinopharm Group Co Ltd
|
Revenue
|
591.6B
CNY
|
|
Cost of Revenue
|
-542.6B
CNY
|
|
Gross Profit
|
49B
CNY
|
|
Operating Expenses
|
-26.1B
CNY
|
|
Operating Income
|
22.9B
CNY
|
|
Other Expenses
|
-14B
CNY
|
|
Net Income
|
8.9B
CNY
|
Free Cash Flow Analysis
Sinopharm Group Co Ltd
What is Free Cash Flow?
Profitability Score
Profitability Due Diligence
Sinopharm Group Co Ltd's profitability score is 50/100. The higher the profitability score, the more profitable the company is.
Score
Sinopharm Group Co Ltd's profitability score is 50/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Sinopharm Group Co Ltd's solvency score is 50/100. The higher the solvency score, the more solvent the company is.
Score
Sinopharm Group Co Ltd's solvency score is 50/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Sinopharm Group Co Ltd
According to Wall Street analysts, the average 1-year price target for
Sinopharm Group Co Ltd
is 27.69 HKD
with a low forecast of 22.07 HKD and a high forecast of 34.01 HKD.
Shareholder Return
Price
Sinopharm Group Co Ltd
| Average Annual Return | -5.36% |
| Standard Deviation of Annual Returns | 21.8% |
| Max Drawdown | -52% |
| Market Capitalization | 66.2B HKD |
| Shares Outstanding | 3 120 656 000 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Sinopharm Group Co Ltd
Country
Industry
Market Cap
Dividend Yield
Description
Sinopharm Group Co., Ltd. is a distributor of pharmaceutical and healthcare products and a value added supply chain service provider in the People's Republic of China. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2009-09-23. The firm operates its business through four segments. Pharmaceutical Distribution segment is engaged in the distribution of pharmaceutical products to hospitals, other distributors, retail pharmacy stores and clinics. Medical Devices segment is engaged in the distribution of medical devices, as well as provides installation and maintenance services. Retail Pharmacy segment is engaged in the operation of chain pharmacy stores. Other Business segment is engaged in the distribution of laboratory supplies, manufacture and distribution of chemical reagents, production and sale of pharmaceutical products.
Contact
IPO
Employees
Officers
The intrinsic value of one
Sinopharm Group Co Ltd
stock under the Base Case scenario is
92.2
HKD.
Compared to the current market price of 21.2 HKD,
Sinopharm Group Co Ltd
is
Undervalued by 77%.
You don't have any saved screeners yet
